Increased carbamylation level of HDL in end-stage renal disease: Carbamylated-HDL attenuated endothelial cell function

American Journal of Physiology - Renal Physiology

Volumn 310, Issue 6, 2016, Pages F511-F517

  Sun, Jia Teng ^a   Yang, Ke ^a   Lu, Lin ^a   Zhu, Zheng Bin ^a   Zhu, Jin Zhou ^a   Ni, Jing Wei ^a   Han, Hui ^a   Chen, Nan ^a   Zhang, Rui Yan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Carbamylation; End stage renal disease; Endothelial repair; High density lipoprotein

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL; UREA; VASCULOTROPIN RECEPTOR 2; ARYLDIALKYLPHOSPHATASE; CYANIC ACID DERIVATIVE; PON1 PROTEIN, HUMAN; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ADULT; ANGIOGENESIS; ARTICLE; CARBAMOYLATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; END STAGE RENAL DISEASE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

AGED; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CYANATES; ENDOTHELIAL CELLS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; SCAVENGER RECEPTORS, CLASS B; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84980396098     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00508.2015     Document Type: Article

References (43)

1. Apostolov EO, Shah SV, Ok E, Basnakian AG. Carbamylated lowdensity lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 27: 826-832, 2007
2. Arnaoutova I, George J, Kleinman HK, Benton G. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis 12: 267-274, 2009
3. Aviram M, Rosenblat M. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol 477: 259-276, 2008
4. Balion CM, Draisey TF, Thibert RJ. Carbamylated hemoglobin and carbamylated plasma protein in hemodialyzed patients. Kidney Int 53: 488-495, 1998
5. Berg AH, Drechsler C, Wenger J, Buccafusca R, Hod T, Kalim S, Ramma W, Parikh SM, Steen H, Friedman DJ, Danziger J, Wanner C, Thadhani R, Karumanchi SA. Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 5: 175ra129, 2013
6. Carracedo J, Merino A, Briceno C, Soriano S, Buendia P, Calleros L, Rodriguez M, Martin-Malo A, Aljama P, Ramirez R. Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J 25: 1314-1322, 2011
7. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 325: 163-167, 2003
8. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27-III32, 2004
9. Drechsler C, Kalim S, Wenger JB, Suntharalingam P, Hod T, Thadhani RI, Karumanchi SA, Wanner C, Berg AH. Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease. Kidney Int 87: 1201-1208, 2015
10. El-Gamal D, Holzer M, Gauster M, Schicho R, Binder V, Konya V, Wadsack C, Schuligoi R, Heinemann A, Marsche G. Cyanate is a novel inducer of endothelial icam-1 expression. Antioxid Redox Signal 16: 129-137, 2012
11. El-Gamal D, Rao SP, Holzer M, Hallstrom S, Haybaeck J, Gauster M, Wadsack C, Kozina A, Frank S, Schicho R, Schuligoi R, Heinemann A, Marsche G. The urea decomposition product cyanate promotes endothelial dysfunction. Kidney Int 86: 923-931, 2014
12. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003
13. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9: S16-23, 1998
14. Gajjala PR, Fliser D, Speer T, Jankowski V, Jankowski J. Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. Nephrol Dial Transplant 30: 1814-1824, 2015
15. Gilbert RE. Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications. Circ J 77: 849-856, 2013
16. Hawkins CL. Role of cyanate in the induction of vascular dysfunction during uremia: more than protein carbamylation? Kidney Int 86: 875-877, 2014
17. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19: 2003-2012, 2007
18. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, Heinemann A, Marsche G. Uremia alters HDL composition and function. J Am Soc Nephrol: 1631-1641, 2011
19. Holzer M, Gauster M, Pfeifer T, Wadsack C, Fauler G, Stiegler P, Koefeler H, Beubler E, Schuligoi R, Heinemann A, Marsche G. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 14: 2337-2346, 2011
20. Holzer M, Schilcher G, Curcic S, Trieb M, Ljubojevic S, Stojakovic T, Scharnagl H, Kopecky CM, Rosenkranz AR, Heinemann A, Marsche G. Dialysis modalities and HDL composition and function. J Am Soc Nephrol: 2267-2276, 2015
21. Holzer M, Zangger K, El-Gamal D, Binder V, Curcic S, Konya V, Schuligoi R, Heinemann A, Marsche G. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional highdensity lipoprotein. Antioxid Redox Signal 17: 1043-1052, 2012
22. Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen RM, Vickers KC, Yancey PG, Linton MF, Fazio S, Kon V. Dysfunctional highdensity lipoproteins in children with chronic kidney disease. Metabolism 64: 263-273, 2015
23. Koeth RA, Kalantar-Zadeh K, Wang Z, Fu X, Tang WH, Hazen SL. Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol 24: 853-861, 2013
24. Lundquist P, Backman-Gullers B, Kagedal B, Nilsson L, Rosling H. Fluorometric determination of cyanate in plasma by conversion to 2,4(1H,3H)-quinazolinedione and separation by high-performance liquid chromatography. Anal Biochem 211: 23-27, 1993
25. Mineo C, Shaul PW. Novel biological functions of high-density lipoprotein cholesterol. Circ Res 111: 1079-1090, 2012
26. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8: 222-232, 2011
27. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371, 2006
28. Pan B, Ma Y, Ren H, He Y, Wang Y, Lv X, Liu D, Ji L, Yu B, Wang Y, Chen YE, Pennathur S, Smith JD, Liu G, Zheng L. Diabetic HDL is dysfunctional in stimulating endothelial cell migration and proliferation due to down regulation of SR-BI expression. PLos One 7: e48530, 2012
29. Prosser HC, Tan JT, Dunn LL, Patel S, Vanags LZ, Bao S, Ng MK, Bursill CA. Multifunctional regulation of angiogenesis by high-density lipoproteins. Cardiovasc Res 101: 145-154, 2014
30. Ren S, Shen GX. Impact of antioxidants and HDL on glycated LDLinduced generation of fibrinolytic regulators from vascular endothelial cells. Arterioscler Thromb Vasc Biol 20: 1688-1693, 2000
31. Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res 54: 3227-3243, 2013
32. Rosenblat M, Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors 35: 98-104, 2009
33. Rye KA, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res 55: 168-179, 2014
34. Santoro D, Bellinghieri G, Conti G, Pazzano D, Satta E, Costantino G, Savica V. Endothelial dysfunction in chronic renal failure. J Ren Nutr 20: S103-S108, 2010
35. Seetharam D, Mineo C, Gormley AK, Gibson LL, Vongpatanasin W, Chambliss KL, Hahner LD, Cummings ML, Kitchens RL, Marcel YL, Rader DJ, Shaul PW. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res 98: 63-72, 2006
36. Sirpal S. Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease. Clin Sci (Lond) 116: 681-695, 2009
37. Speer T, Owala FO, Holy EW, Zewinger S, Frenzel FL, Stahli BE, Razavi M, Triem S, Cvija H, Rohrer L, Seiler S, Heine GH, Jankowski V, Jankowski J, Camici GG, Akhmedov A, Fliser D, Luscher TF, Tanner FC. Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J 35: 3021-3032, 2014
38. Tan JT, Prosser HC, Vanags LZ, Monger SA, Ng MK, Bursill CA. High-density lipoproteins augment hypoxia-induced angiogenesis via regulation of post-translational modulation of hypoxia-inducible factor 1alpha. FASEB J 28: 206-217, 2014
39. Tolle M, Huang T, Schuchardt M, Jankowski V, Prufer N, Jankowski J, Tietge UJ, Zidek W, van der Giet M. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatoryserum amyloid A. Cardiovasc Res 94: 154-162, 2012
40. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13: 1176-1184, 2007
41. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Doller D, Katholnig K, Suarna C, Eller P, Tolle M, Gerner C, Zlabinger GJ, van der Giet M, Horl WH, Stocker R, Saemann MD. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 23: 934-947, 2012
42. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 60: 2372-2379, 2012
43. Zenovich AG, Taylor DA. Atherosclerosis as a disease of failed endogenous repair. Front Biosci 13: 3621-3636, 2008